Copyright Reports & Markets. All rights reserved.

Global Antisense and RNAi Therapeutics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Antisense and RNAi Therapeutics

      • 1.1 Definition of Antisense and RNAi Therapeutics
      • 1.2 Antisense and RNAi Therapeutics Segment by Type
        • 1.2.1 Global Antisense and RNAi Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 RNA Interference
        • 1.2.3 Antisense RNA
      • 1.3 Antisense and RNAi Therapeutics Segment by Applications
        • 1.3.1 Global Antisense and RNAi Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
      • 1.4 Global Antisense and RNAi Therapeutics Overall Market
        • 1.4.1 Global Antisense and RNAi Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Antisense and RNAi Therapeutics Production (2014-2025)
        • 1.4.3 North America Antisense and RNAi Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Antisense and RNAi Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Antisense and RNAi Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Antisense and RNAi Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Antisense and RNAi Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Antisense and RNAi Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Antisense and RNAi Therapeutics
      • 2.3 Manufacturing Process Analysis of Antisense and RNAi Therapeutics
      • 2.4 Industry Chain Structure of Antisense and RNAi Therapeutics

      3 Development and Manufacturing Plants Analysis of Antisense and RNAi Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Antisense and RNAi Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Antisense and RNAi Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Antisense and RNAi Therapeutics Production and Capacity Analysis
      • 4.2 Antisense and RNAi Therapeutics Revenue Analysis
      • 4.3 Antisense and RNAi Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Antisense and RNAi Therapeutics Regional Market Analysis

      • 5.1 Antisense and RNAi Therapeutics Production by Regions
        • 5.1.1 Global Antisense and RNAi Therapeutics Production by Regions
        • 5.1.2 Global Antisense and RNAi Therapeutics Revenue by Regions
      • 5.2 Antisense and RNAi Therapeutics Consumption by Regions
      • 5.3 North America Antisense and RNAi Therapeutics Market Analysis
        • 5.3.1 North America Antisense and RNAi Therapeutics Production
        • 5.3.2 North America Antisense and RNAi Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Antisense and RNAi Therapeutics Import and Export
      • 5.4 Europe Antisense and RNAi Therapeutics Market Analysis
        • 5.4.1 Europe Antisense and RNAi Therapeutics Production
        • 5.4.2 Europe Antisense and RNAi Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Antisense and RNAi Therapeutics Import and Export
      • 5.5 China Antisense and RNAi Therapeutics Market Analysis
        • 5.5.1 China Antisense and RNAi Therapeutics Production
        • 5.5.2 China Antisense and RNAi Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Antisense and RNAi Therapeutics Import and Export
      • 5.6 Japan Antisense and RNAi Therapeutics Market Analysis
        • 5.6.1 Japan Antisense and RNAi Therapeutics Production
        • 5.6.2 Japan Antisense and RNAi Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Antisense and RNAi Therapeutics Import and Export
      • 5.7 Southeast Asia Antisense and RNAi Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Antisense and RNAi Therapeutics Production
        • 5.7.2 Southeast Asia Antisense and RNAi Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Antisense and RNAi Therapeutics Import and Export
      • 5.8 India Antisense and RNAi Therapeutics Market Analysis
        • 5.8.1 India Antisense and RNAi Therapeutics Production
        • 5.8.2 India Antisense and RNAi Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Antisense and RNAi Therapeutics Import and Export

      6 Antisense and RNAi Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Antisense and RNAi Therapeutics Production by Type
      • 6.2 Global Antisense and RNAi Therapeutics Revenue by Type
      • 6.3 Antisense and RNAi Therapeutics Price by Type

      7 Antisense and RNAi Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Antisense and RNAi Therapeutics Consumption by Application
      • 7.2 Global Antisense and RNAi Therapeutics Consumption Market Share by Application (2014-2019)

      8 Antisense and RNAi Therapeutics Major Manufacturers Analysis

      • 8.1 Tekmira Pharmaceuticals
        • 8.1.1 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.1.2 Tekmira Pharmaceuticals Product Introduction, Application and Specification
        • 8.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Arbutus Biopharma
        • 8.2.1 Arbutus Biopharma Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.2.2 Arbutus Biopharma Product Introduction, Application and Specification
        • 8.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Alnylam Pharmaceuticals
        • 8.3.1 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.3.2 Alnylam Pharmaceuticals Product Introduction, Application and Specification
        • 8.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Antisense Therapeutics
        • 8.4.1 Antisense Therapeutics Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.4.2 Antisense Therapeutics Product Introduction, Application and Specification
        • 8.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Silence Therapeutics
        • 8.5.1 Silence Therapeutics Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.5.2 Silence Therapeutics Product Introduction, Application and Specification
        • 8.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Isis Pharmaceuticals
        • 8.6.1 Isis Pharmaceuticals Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.6.2 Isis Pharmaceuticals Product Introduction, Application and Specification
        • 8.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Sirnaomics
        • 8.7.1 Sirnaomics Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.7.2 Sirnaomics Product Introduction, Application and Specification
        • 8.7.3 Sirnaomics Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Santaris
        • 8.8.1 Santaris Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.8.2 Santaris Product Introduction, Application and Specification
        • 8.8.3 Santaris Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Roche
        • 8.9.1 Roche Antisense and RNAi Therapeutics Production Sites and Area Served
        • 8.9.2 Roche Product Introduction, Application and Specification
        • 8.9.3 Roche Antisense and RNAi Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served

      9 Development Trend of Analysis of Antisense and RNAi Therapeutics Market

      • 9.1 Global Antisense and RNAi Therapeutics Market Trend Analysis
        • 9.1.1 Global Antisense and RNAi Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Antisense and RNAi Therapeutics Regional Market Trend
        • 9.2.1 North America Antisense and RNAi Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Antisense and RNAi Therapeutics Forecast 2019-2025
        • 9.2.3 China Antisense and RNAi Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Antisense and RNAi Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Antisense and RNAi Therapeutics Forecast 2019-2025
        • 9.2.6 India Antisense and RNAi Therapeutics Forecast 2019-2025
      • 9.3 Antisense and RNAi Therapeutics Market Trend (Product Type)
      • 9.4 Antisense and RNAi Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Antisense and RNAi Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The rising incidence of coronary artery diseases, cardiac ailments, and neurodegenerative and infectious diseases has led to the demand for antisense and RNai therapeutics. The market exhibits a strong pipeline of product and is looking forward to introduce several advancements in the RNAi drug delivery technology.
        The potential commercialization of a few candidates under research and development will help the antisense and RNAi therapeutics market to pick up pace in North America in the near future.

        The global Antisense and RNAi Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Antisense and RNAi Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antisense and RNAi Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Antisense and RNAi Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Antisense and RNAi Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Tekmira Pharmaceuticals
        Arbutus Biopharma
        Alnylam Pharmaceuticals
        Antisense Therapeutics
        Silence Therapeutics
        Isis Pharmaceuticals
        Sirnaomics
        Santaris
        Roche

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        RNA Interference
        Antisense RNA

        Segment by Application
        Hospital
        Clinic

        Buy now